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ABSTRACT
Recent improvements in next-generation sequencing (NGS) technology have
enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace
invasive tissue biopsies. However, a better understanding of the performance of
blood-based NGS assays is needed prior to routine clinical use. As part of an IRBapproved molecular profiling registry trial of pancreatic ductal adenocarcinoma
(PDA) patients, we facilitated blood-based NGS testing of 34 patients from multiple
community-based and high-volume academic oncology practices. 23 of these patients
also underwent traditional tumor tissue-based NGS testing. cfDNA was not detected
in 9/34 (26%) patients. Overall concordance between blood and tumor tissue NGS
assays was low, with only 25% sensitivity of blood-based NGS for tumor tissue NGS.
Mutations in KRAS, the major PDA oncogene, were only detected in 10/34 (29%)
blood samples, compared to 20/23 (87%) tumor tissue biopsies. The presence of
mutations in circulating DNA was associated with reduced overall survival (54% in
mutation-positive versus 90% in mutation-negative). Our results suggest that in the
setting of previously treated, advanced PDA, liquid biopsies are not yet an adequate
substitute for tissue biopsies. Further refinement in defining the optimal patient
population and timing of blood sampling may improve the value of a blood-based test.

INTRODUCTION

leading cause of cancer-related death by 2025 [1]. This
is, in part, due to poor early detection strategies: most
cases are detected at an advanced stage [2] despite the
long amount of time required for metastatic disease

Pancreatic ductal adenocarcinoma (PDA) is an
aggressive cancer that is projected to become the second
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to develop [3]. However, even resectable pancreatic
cancers usually recur [2]. The current standard of care
therapies for metastatic disease are comprised of cytotoxic
chemotherapies, but despite recent improvements, the
median overall survival remains less than one year [4,
5]. In theory, personalized therapy for PDA promises a
more rational approach than “standard of care” treatment,
by identifying and targeting “actionable” or “driver”
mutations.
With the advent of new commercially available
CLIA/CAP accredited lab testing for next-generation
sequencing (NGS) panels, detection of actionable
mutations from tissue biopsies no longer requires that
the patient be seen at a specialized high-volume tertiary
care academic medical center. Still, potential obstacles
in detecting mutations from patient samples include the
tumor not being accessible via biopsy and/or not enough
tumor cells being extracted for DNA analysis. A potential
solution for these problems is the development of “liquid
biopsy” techniques that use the same NGS technologies
for molecular profiling. Detection of circulating tumor
DNA (ctDNA) in cell-free DNA (cfDNA), circulating
tumor cells (ctcDNA), and tumor exosome-containing
genomic material has created the possibility of a noninvasive method for diagnosing and monitoring cancer [6].
We previously launched an initiative (Know
Your Tumor, a collaboration between Perthera and the
Pancreatic Cancer Action Network), which includes
multi-omic molecular profiling of PDA patients’ tumors
and matches patients with appropriate clinical trials
and therapies based on actionable molecular anomalies,
treatment history and geographical locations. However,
to effectively implement this precision medicine strategy,
biopsy samples with relatively high levels of tumor cells
are needed, forcing us to exclude PDA patients with
locally advanced disease, or those with small volume,
non-biopsiable disease. As a promising solution, we
evaluated two CLIA/CAP accredited blood-based NGS
assays as a potential substitute for gold standard tissue
biopsy procedures. Here we describe our experience with
a pilot study of 34 PDA patients that represent a “real
world” setting of consecutive patients with metastatic,
disseminated disease in community and academic settings
from locations across the United States.

medicine strategy for pancreatic cancer, blood-based
NGS assays were performed on 34 patients. Blood draws
were sent to commercial laboratories for NGS analysis
by the Guardant Health Guardant360 test (n = 26) or the
Cynvenio ClearID test (n = 8). Hereafter, these assays
will be referred to as the cfDNA-based NGS assay
and the ctcDNA-based NGS assay, respectively. The
majority of patients had extensive disease burden that
had metastasized to the liver, lung, or peritoneal cavity.
However, several patients had either localized disease
or no detectable disease due to distal pancreatectomy or
Whipple procedure (Table 1 and Table S1). In 57% of
cases (13/23), blood samples were collected within six
weeks of the tumor biopsy, and, importantly in 74% of
cases (17/23), blood samples were collected while the
patient’s clinical condition (extent of disease, and response
to therapy) had not changed since the tumor biopsies
(Table S1).

Concordance between blood-based and tumor
tissue biopsies
In the 19 patients with detectable tumor mutations in
cfDNA, mutations were found in a median of 2 genes per
patient (Figure 1 and Table S2). This number was lower
than tumor tissue biopsies, in which a median of 13 genes
per patient had mutations. A probable reason for the lower
number of mutations in the cfDNA-based assay is that the
panel had 68 genes while the panel used for tumor tissue
NGS had 321 genes. After normalizing by the number
of genes on each panel, the median frequency of altered
genes per panel was similar (2.9% for the cfDNA-based
NGS assay and 4.0% for the tissue-based NGS assay).
However, in general there was no correlation between
the number of mutations found in cfDNA and in tumor
tissue (Figure 1A). We therefore focused on analyzing
concordance in overlapping genes.

Detection of KRAS mutations by blood-based
NGS
We analyzed concordance between blood-based
and tumor tissue biopsies in the 23 patients that had both
blood-based and tumor tissue NGS analyses. We first
examined four of the most frequently altered genes in
pancreatic cancer, KRAS, TP53, CDKN2A, and SMAD4
(Figure 1D). In the patients with both blood-based and
tumor tissue NGS, nine (39%) were concordant for KRAS
status (6 mutants and 3 wild-type). The blood-based NGS
assays did not detect 14 KRAS variants (61%) that were
present in the tumor tissue. We noted that in patients
for whom KRAS mutations were detected in both tumor
tissue and blood, all tumor samples were biopsied from

RESULTS
Feasibility of performing blood-based NGS assays
from PDA patients regardless of the clinical
setting
To evaluate the feasibility of incorporating
circulating DNA-based NGS assays into a precision
www.impactjournals.com/oncotarget
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Table 1: Patient characteristics.
cfDNA-based NGS
(N = 26)
Gender
Male

ctcDNA-based
NGS
(N = 8)

13

5

Female

13

3

66.5
48 – 83

63
30 – 74

17
6
3

7
0
1

10
9
7

5
3
0

9
2
2
2
1

5
1
1
0
0

19
7

8
0

Age, years
Median
Range
Disease Burden
Extensive
Localized/Minimal
None
Status at Blood Draw
Progressing
Stable
Responding
Tumor Biopsy Site
Liver
Pancreas
Lung
Peritoneum
Duodenum
Treatment Setting
Hospital
Community Practice

Tumor biopsy sites are only listed for patients with tumor tissue NGS data. Patients
with disease burden listed as “None” were those that had undergone pancreatectomy
or Whipple procedures and had no evidence of recurrence.
liver metastases (Table S4). The low detection rate of
KRAS mutations in circulating DNA is problematic since
this gene is mutated in over 90% of PDA tumors in most
reports [7, 8].
To determine whether technical limitations played
a part in the low rate of detection of KRAS mutations
plasma cfDNA, we examined the sequencing quality
metrics where possible. The median sequencing coverage
for KRAS mutations in tumor tissue sequenced using the
FoundationOne panel was 845x, with only one sample
below 500x, in line with the analytical validation study
published by Foundation Medicine [9]. Quality control
metrics were not obtainable for the Guardant360 assay,
but validation of the assay has demonstrated a depth of
coverage of 8, 000X and a limit of detection of 0.25%
[10]. For the ClearID assay, the cell-free DNA yield from
the plasma samples (n = 8) ranged from 1.2 to 10 ng. Of
the 4 patients with tumor tissue KRAS mutations but no
cfDNA KRAS mutations, one of them had a low cell-free
DNA yield (1.7 ng), while the other three had high yields
(>8 ng) that were similar to the two patients with KRAS
mutations detected in both plasma and tumor tissue. This
indicates that both technological (low cfDNA yields) and
biological (actual lack of KRAS mutations in the plasma)
www.impactjournals.com/oncotarget

limitations likely play a role.

Identification of well-established PDA drivers in
cfDNA analysis
In the 23 patients with both blood-based and tumor
tissue NGS, six (26.1%) were concordant for TP53 status
(3 mutants and 4 wild-type). The blood-based NGS
assays did not detect 15 TP53 variants (65.2%) that were
present in the tumor tissue. The three concordant TP53
variants were G325*, V272L, and R273C (Figure S1).
Three patients had differing TP53 mutations in cfDNAbased and tumor tissue NGS: pan-545 (G389G in cfDNA,
S261fs*2 in tumor), pan-594 (H193L and V272L in
cfDNA, only V272L in tumor), and pan-598 (P278S in
cfDNA, P153fs*28 in tumor).
No mutations in CDKN2A or SMAD4 were detected
in the blood-based assays (Figure 1D). Mutations in these
genes were detected in tumor tissue in 11/23 (47.8%) and
6/23 (26.1%) patients, respectively. A possible reason for
the absence of these variants in the blood-based NGS
analysis is that the assays are not validated for gene
deletions, indels, or splice site mutations. Many of the
83448
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CDKN2A (8/11, 73%) and SMAD4 (4/6, 67%) variants
detected by tissue-based NGS were deletions, indels, or
splice site mutations and thus would not be expected to be
detected by the blood-based NGS assays.

cfDNA and tumor tissue NGS data were available. Also,
to be consistent with methodologies described previously
[10, 11], we only considered the patients in which tumor
DNA was actually detected in cfDNA, reducing the
number of patients under consideration to 11. We removed
a number of alterations from the tumor tissue NGS data
prior to assessing sensitivity and precision: we removed
any gene not included on the cfDNA assay panel; we
removed deletions, indels, and rearrangements (the cfDNA
panel only detects point mutations and amplifications);
we removed tumor tissue amplifications for genes whose
copy number could not be determined by the cfDNA
assay (amplifications can only be assessed for a subset of
genes on the cfDNA panel); and we removed tumor tissue

Sensitivity and precision of cfDNA-based NGS for
tumor biopsy mutations
To systematically assess the performance of bloodbased NGS assays across all genes, we determined the
sensitivity and specificity of the cfDNA-based assay
using the tumor tissue NGS data as the reference. For this
analysis, we only considered the patients for whom both

Figure 1: Panel-normalized number of alterations detected in liquid and tumor tissue biopsies. A. On average, more

variants were detected in the tumor tissue biopsy (red) than the cfDNA-based assay (blue) in patients with data from both assays available.
Panel normalization was performed by dividing the number of mutations detected in each patient by the number of genes on the panel (N
= 321 for tumor tissue, N = 68 for cfDNA, and N = 50 for ctcDNA). B. The number of variants detected in the patients for whom only the
cfDNA-based assay was performed was similar to that of the cfDNA-based assays in panel A. C. More variants were detected in the tumor
tissue biopsy (red) than the ctcDNA-based assay (blue). No tumor tissue biopsy was available for the last patient listed, pan-774. D. The
pancreatic cancer driver genes KRAS, TP53, SMAD4, and CDKN2A were detected less frequently in cfDNA-based biopsies. Patients are
subdivided according to which biopsies were performed: patients for whom both cfDNA and tumor tissue biopsies were obtained are in the
left block, while patients for whom only cfDNA biopsies were obtained are in the middle block, and patients with both ctcDNA and tumor
tissue biopsies are in the right block. Patients for whom tumor quantity was insufficient for tissue-based NGS are shaded in gray. Disease
burden and treatment response were determined based on the most recent CT scans prior to drawing of blood samples.
www.impactjournals.com/oncotarget
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Figure 2: Precision and sensitivity of cfDNA-based NGS assay in detection of tumor tissue variants. The precision (A)
andsensitivity (B) were calculated for each gene listed in the middle using the formula at the bottom of the respective panel. TP indicates the
number of true positives, or concordant variants; FP indicates false positives, or the number of variants in cfDNA but not present in tumor
tissue; FN indicates false negatives, or the number of variants in tumor tissue but not in cfDNA.
www.impactjournals.com/oncotarget
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Table 2: Comparison of concordance in published liquid biopsy studies.
Zill et al. 2015 [11]
(N = 26)

Lanman et al. 2015 [10]
(N = 165)

Cancer Type

18 PDA
8 Biliary

Stage

3 Stage III
23 Stage IV

Tumor Biopsy Site

11 Primary
15 Metastasis

57 Colorectal
22 Other GI
86 Other
40 Stage III
120 Stage IV
5 Unknown

Patient Characteristics

Info
Assay
Commercial Lab
Liquid-Tumor Comparison
Overall Sensitivity
KRAS Sensitivity

Bettegowda et al. 2014 [23]
(N = 206)

206 Colorectal
206 Stage IV

Unspecified

Unspecified

cfDNA
Guardant Health

cfDNA
Guardant Health

cfDNA
PGDx

92.3%
100%

85%
88%

Unspecified
87.2%

mutations in exons not covered by the cfDNA panel. After
these filters were applied, the remaining dataset consisted
of 55 alterations across 25 genes.
The precision and sensitivity of the cfDNA-based
NGS assay could only be evaluated for the five genes
for which concordant variants occurred; the remaining
20 genes were only observed in one of the two assays.
Precision, defined as the proportion of cfDNA-based
mutations that were detected in both assays, was 100% for
KRAS and MYC (Figure 2A), although there was only one
MYC alteration. Sensitivity, defined as the proportion of
tumor tissue-based mutations that were detected by both
assays, was 100% for EGFR (Figure 2B), although there
was only one EGFR alteration. The remaining genes had
low values of sensitivity and precision. The high precision/
low sensitivity for KRAS indicated that a KRAS variant
detected by the cfDNA-based NGS assay is likely present
in the tumor tissue, although the absence of a KRAS
variant in cfDNA does not necessarily imply a lack of
KRAS mutations in tumor tissue. The overall precision and
sensitivity across all 25 overlapping genes were 40% and
25%, respectively.

EGFR, FGFR1, FLT3, and PDGFRA, which may indicate
sensitivity to various tyrosine kinase inhibitors [17-21].
Consistent with the low overall concordance we observed
between cfDNA and tumor tissue NGS data, only one
actionable mutation was detected in the same patient by
both assays, an EGFR amplification in patient pan-545
(Figure 3).
In ten patients with cfDNA analysis and no tumor
tissue biopsies, three actionable mutations were found
(Figure 3, middle panel). In eight patients with ctcDNA
analysis, tumor tissue-based NGS revealed four actionable
markers, none of which were detected by the ctcDNA
assay (Figure 3, right panel). These discrepancies between
tumor tissue-based and blood-based NGS assays indicate
that further technical improvements are needed before
blood-based NGS assays can be successfully applied in
therapeutic decision-making.

Impact of clinical variables on the detection of
tumor DNA in plasma
Mutations in circulating DNA were only detected
in blood-based NGS analysis of 25 (74%) of the patients:
19 out of 26 (73%) by the cfDNA-based assay and 6 out
of 8 (75%) by the ctcDNA-based assay. Since one of our
goals is to detect actionable mutations that can influence
treatment decisions, it is critical to know when a bloodbased assay is most likely to detect specific tumor DNA
mutations. Therefore we explored the clinical factors
related to the presence or absence of detectable mutations
in the blood. We used the maximum variant allele fraction
in the blood-based assays as a surrogate for level of
tumor DNA in the blood [10]. The patients with the six
highest frequencies of somatic alterations in circulating
DNA had extensive disease that was present in both the

Therapeutic implications for assays tested
We examined mutations that confer drug sensitivity
to explore differences in the therapeutic implications
derived from cfDNA-based and tumor tissue-based NGS
assays. These actionable mutations included ATM and
PALB2, which may indicate sensitivity to PARP inhibitors
[12] or platinum agents [13]; CCND2, CDK4, and CDK6,
which may indicate sensitivity to CDK inhibitors [14,
15]; AKT1, AKT2, ARID1A, PIK3CA, PIK3CG, and
STK11, which may indicate sensitivity to PI3K/mTOR
inhibitors [16]; and the receptor tyrosine kinases AXL,
www.impactjournals.com/oncotarget
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pancreas and distal metastases (Figure 4A). However,
ten patients with extensive disease had no detectable
tumor DNA in the blood. Several other clinical variables,
including current treatment response status, time since
most recent treatment, time since diagnosis, and type of
most recent therapy, were not correlated with the presence
of mutations in circulating DNA (Figure S3). There was a
weak correlation (Pearson’s R = 0.41) between the level of
CA19-9 marker and the maximum variant allele fraction
(Figure S3C). While a larger sample size is needed to draw
definitive conclusions, these results indicate that clinical
covariates may lack strong associations with the presence
or absence of mutations in cfDNA and therefore may not
be sufficient indicators of whether a blood-based NGS
assay will reliably detect tumor mutations.

in circulating DNA (n = 24), with 11 deaths occurring in
this subgroup compared to one in the subgroup with no
detectable tumor DNA (n = 10) (Figure 4B, log-rank P
= 0.045). The prognostic significance of the presence of
mutations in the circulation highlights a possible role for
blood-based NGS in clinical care of pancreatic cancer
patients, in keeping with the recent role for CTC analysis
in monitoring disease burden [22].

DISCUSSION
Despite the promise of noninvasive liquid biopsies,
our data suggest that circulating DNA-based NGS assays
do not yet appear ready to replace tumor tissue biopsies
in detecting actionable mutations for use in pancreatic
cancer precision oncology strategies. We analyzed a pilot
study set of consecutively enrolled patients with metastatic
PDA who were enrolled in a “real-world“ community
setting, which represents the exact type of target patient
population that would be most impacted by these
evolving molecular practices given the high percentage
of metastatic cancer patients treated at the community
level. The low concordance between cfDNA-based and
tumor tissue NGS assays in our data would yield lower
numbers of actionable mutations if only the cfDNA-based

Correlation of cfDNA mutations with prognosis
Although the disease burden did not appear to
be strongly predictive of the presence of mutations in
circulating DNA, the presence of mutations did have
prognostic significance. Outcome data was available for
all patients with a median follow-up (time since blood
sampling) of 28 weeks. Overall survival was lower in
the subset of patients in which mutations were detected

Figure 3: Detection of actionable mutations. Variants with therapeutic implications were detected in both tumor tissue and cfDNA.

Patients are subdivided into those with tumor tissue and cfDNA data (left block), cfDNA only (middle block), and tumor tissue and ctcDNA
(right block). Variants found in tumor tissue NGS analysis are indicated by a red square, variants found in cfDNA-based NGS analysis are
indicated by a blue square, and the sole concordant variant is indicated by a half-red/half-blue square. Patients for whom tumor quantity
was insufficient for tissue-based NGS are shaded in gray.
www.impactjournals.com/oncotarget
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assay data were available. Given the high frequency of
KRAS mutations in PDA of over 90% in most reports [7,
8], we can use this specific genomic alteration as a gold
standard to gauge technical utility, which provides a
unique window into cfDNA-tumor tissue concordances.
Our results showed poor sensitivity of cfDNA bloodbased testing to identify KRAS mutations. However, we
did find evidence for potential clinical utility based on the
prognostic significance that we observed (Figure 5B).
Several performance characteristics of bloodbased NGS analysis were similar in our study and other
published studies that used the same commercial cfDNAbased NGS assay. Mutations in blood were detected
in 73% of the cfDNA-based NGS assays here, while in
other studies this frequency was 86% [10] and 96% [11].
We found a median of 2 mutated genes per patient in the
cfDNA-based NGS assay, while other studies found means
of 3.3 [10] and 2.8 [11] altered genes per patient.
A major difference between our data and other
studies is the very low concordance of genomic alterations
found between liquid and tumor tissue biopsies (Table 2).
One study of 165 patients demonstrated 85% sensitivity
and 80.7% precision in detecting tumor tissue variants
using cfDNA-based NGS [10]. Another study involving
17 pancreatic and biliary cancer patients reported an
overall sensitivity of 90.3% and an overall precision of
87.5% [11]. A highly specific digital PCR method has
been used to sequence the plasma cfDNA of pancreatic
cancer patients with known KRAS mutations, finding
KRAS mutations in the plasma of 30/34 (88%) patients
with metastatic disease and 59/121 (49%) patients with
localized disease (precision could not be evaluated

because all patients had KRAS mutations) [23]. Our
sensitivity and precision were much lower, indicating that
many mutations would be missed in our patient cohort
without tumor tissue NGS analysis. We also note that
it is difficult to attribute the low KRAS detection rate in
our study to technological versus biological limitations.
However, the yield of cell-free DNA may be useful in this
regard: in the ctcDNA-based NGS assay, one of the four
patients with tumor tissue KRAS mutations not present
in the plasma had a low yield of cfDNA, suggestive of
technological limitations. The other three patients with
high cfDNA yields in plasma may therefore be patients
for whom tumor cells were not actively shedding DNA. A
larger sample size will be required to determine if there is
a significant association between plasma cfDNA yield and
the sensitivity of detection of tumor mutations. In addition
to the low sensitivity for tumor mutations that should be
detectable by the blood-based NGS assay, there is a further
limitation in that deletions, indels, and rearrangements
cannot be detected by the blood-based NGS assay (but can
on the tumor tissue NGS assay).
A possible explanation for the low sensitivity is the
heavily pre-treated nature of our patient population: nearly
all of our patients had received some form of systemic
chemotherapy prior to blood-based NGS analysis.
Chemotherapy likely has a strong impact on the levels of
cfDNA, making the detection of mutated cfDNA difficult
in the setting of active therapy, irrespective of the current
extent of radiographic response at the time the blood
sample was obtained. Follow-up studies could include a
stratified population of stage-matched patients comprised
of treatment-naïve patients, patients responding to therapy

Figure 4: Detection of tumor DNA in circulating DNA and prognostic significance in pancreatic cancer patients. A. The

maximum mutant allele fraction in cfDNA or ctcDNA trended higher in patients with extensive disease, although this was not statistically
significant. B. Overall survival trended lower in patients with detectable tumor DNA in cfDNA (ctDNA+, n = 24) than in those with no
detectable tumor DNA (ctDNA-, n = 10), with a total of 11 and 1 deaths, respectively.
www.impactjournals.com/oncotarget
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and patients progressing on first line therapy or beyond.
Our observation that the presence of tumor DNA in
cfDNA is a negative prognostic factor is consistent with
numerous other studies. Multiple studies using digital
PCR have demonstrated that high levels of circulating
KRAS mutations in pancreatic cancer patients adversely
affect survival [24], [25]. Another group used digital PCR
to detect alterations in KRAS, BRAF, and PIK3CA in
pancreatic cancer patients, demonstrating that detection of
any of these genes was associated with lower progressionfree survival [26]. The level of mutated cfDNA is
prognostic in other cancer types as well, with higher levels
of mutated KRAS and BRAF DNA found in colorectal
cancer patients with lower survival [27].
The low concordance between tumor tissue and
cfDNA-based NGS that we observed here indicates that
further technical development is needed in this specific
setting of late-stage pancreatic cancer. Nonetheless,
despite the limitations we observed, we have demonstrated
that it is feasible to utilize blood-based NGS profiling
across many different hospitals and community-based
practices; this is in contrast to other similar studies that
were conducted at large academic institutions [11, 26].
The ability to use the extremely high KRAS mutation
frequency in pancreatic cancer provided us with an
important control to directly assess technical feasibility
of cfDNA based molecular profiling of metastatic cancer
patients where access to tumor tissue may problematic.
Moreover, the ability to measure genomic alterations in
patient matched cfDNA and tumor tissue in consecutively
consented patients that are enrolling in an “all comers”
national program that closely mimic what would be
expected be seen at any point in time in clinics and
physician offices around the United States provides
a unique assessment window. Increasing analytical
sensitivity using techniques such as dPCR could certainly
increase concordance rates and identify molecular
alterations where cfDNA concentrations are low in any
given patient. However at this time, technologies like
dPCR are not readily available in the community setting,
where most patients are being treated. In the future, an
optimized version of these platforms may allow for
application of a personalized therapeutic approach to a
greater number of pancreatic cancer cases, particularly
those in which a tumor biopsy is hard to obtain.

different community oncology practices were enrolled
and data collected in the registry. Patients were enrolled
sequentially, during the time frame of this Pilot program.

MATERIALS AND METHODS

All statistical analysis was performed in R. Survival
differences between patient groups were determined
using the log-rank test on Kaplan-Meier curves with the R
survival package [31]. When performing survival analysis,
follow-up time was defined as the number of weeks since
blood sampling.

Next-generation sequencing of circulating DNA
Whole blood samples were sent to one of two
commercial laboratories for targeted NGS analysis. The
Guardant360 test (Guardant Health, Redwood City, CA)
involves targeted sequencing of a 68-gene panel (Table
S3B) in cfDNA using the Illumina HiSeq 2500 platform
as previously described [28], whereas the ClearID test
(Cynvenio, Westlake Village, CA) involves targeted
sequencing of a 50-gene panel (Table S3C) in ctcDNA
using the IonTorrent PGM platform. In the Guardant360
test, 20 mL whole blood is stabilized in cell-free DNA
BCT tubes (Streck, Omaha, NE), which prevent lysis of
blood cells for up to seven days [29]. In the ClearID test,
20 mL whole blood is collected into K2EDTA tubes and
then stabilized in a proprietary fixative, which allows for
a window of four days between sample collection and
analysis. The Guardant360 assay generates read depths
above 8, 000x and has a detection limit for frequencies
of 0.25% [10]. At an optimal DNA input of 10 ng and
minimum read depth of 500x, the ClearID test is validated
for detecting variants at allele frequencies as low as 1%
[30]. In all but five cases, the labs received the samples
one day after collection; four samples were in transit for
two days, and one sample was in transit for four days.

Next-generation sequencing of tumor tissue
Formalin-fixed, paraffin-embedded tumor tissue
samples were sent to a commercial laboratory for
NGS testing (FoundationOne, Foundation Medicine,
Cambridge, MA), which targets a 321-gene panel (Table
S3A) for sequencing on the Illumina HiSeq 2500 platform.
The overlap between panels was high: 65/68 (95.6%)
genes from the Guardant360 panel were present on the
FoundationOne panel, while 49/50 (98%) genes from the
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